Biosimilars: Can They Break Through?

The report, presented by the Alliance for Patient Access (AfPA) and titled “Biosimilars: Can They Break Through?” will include discussion on the policy issues surrounding biosimilars in the United States. Topics will include:

• Given pending FDA regulations, what are the obstacles in getting biosimilars to market?
  
• What are the concerns surrounding the labeling or prescriber information, and why is the issue of naming so hotly contested?